Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by KBC Group NV

KBC Group NV boosted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 54.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,093 shares of the company’s stock after acquiring an additional 737 shares during the quarter. KBC Group NV’s holdings in Protagonist Therapeutics were worth $81,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Protagonist Therapeutics by 749.2% during the third quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after buying an additional 487 shares during the period. FNY Investment Advisers LLC purchased a new stake in Protagonist Therapeutics during the 4th quarter worth $38,000. Exchange Traded Concepts LLC acquired a new stake in Protagonist Therapeutics in the 3rd quarter valued at $43,000. CWM LLC raised its position in Protagonist Therapeutics by 910.3% in the third quarter. CWM LLC now owns 1,273 shares of the company’s stock valued at $57,000 after purchasing an additional 1,147 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Protagonist Therapeutics during the third quarter worth about $69,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PTGX. StockNews.com lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. JPMorgan Chase & Co. lifted their price objective on shares of Protagonist Therapeutics from $51.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Protagonist Therapeutics in a research note on Friday. BMO Capital Markets initiated coverage on shares of Protagonist Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $62.00 price target on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Insider Activity

In related news, insider Arturo Md Molina sold 26,000 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $44.70, for a total value of $1,162,200.00. Following the sale, the insider now owns 46,444 shares of the company’s stock, valued at $2,076,046.80. This trade represents a 35.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Suneel Gupta sold 103,437 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $46.04, for a total transaction of $4,762,239.48. Following the completion of the transaction, the insider now owns 256,174 shares of the company’s stock, valued at approximately $11,794,250.96. This trade represents a 28.76 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 209,863 shares of company stock valued at $9,689,847. Company insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Stock Up 3.0 %

NASDAQ:PTGX opened at $38.88 on Monday. The company has a market cap of $2.32 billion, a PE ratio of 14.62 and a beta of 2.22. The business’s 50 day moving average is $38.99 and its two-hundred day moving average is $41.91. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $48.89.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The firm had revenue of $4.68 million during the quarter, compared to the consensus estimate of $4.50 million. As a group, sell-side analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.